Latest Research Highlights

Basic Elocon Information

• INN (International Nonproprietary Name): Mometasone furoate
• Brand Names Available In Australia: Elocon; generics (Mometasone Sandoz, Mometasone Teva); other global brands include Momate, Sensicort, Elica (local availability varies)
• ATC Code: D07AC13 (Corticosteroids, potent, group III, for topical use)
• Forms & Dosages: Cream 0.1% (15g, 30g tubes); Ointment 0.1% (15g, 30g tubes); Lotion 0.1% (30mL bottles). Lotions/solutions commonly used for scalp disease.
• Manufacturers In Australia: not specified (original sponsor Organon and multiple global generic manufacturers such as Glenmark, Teva, Sandoz, Akrikhin)
• Registration Status In Australia: not specified (approved and marketed in multiple regions; check TGA ARTG for current local sponsors)
• OTC / Rx Classification: Prescription Only (Rx) in most jurisdictions

Clinicians and patients often ask whether new studies change how Elocon or mometasone furoate should be used.

Recent clinical reviews and real‑world audits from 2022–2025 continue to describe mometasone furoate as an effective potent topical steroid for short‑term control of eczematous and inflammatory dermatoses.

Data synthesised across audits show faster symptomatic relief when mometasone is added to emollient therapy compared with emollient alone.

Safety reporting emphasises low systemic absorption when used as directed, consistent with its topical classification D07AC13.

Paediatric case reports and pharmacovigilance entries highlight the risk of hypothalamic–pituitary–adrenal (HPA) axis suppression, skin atrophy and hypopigmentation with prolonged use, occlusion or application over large areas — especially in children.

Australian observational data remain limited, so many reviews combine international trial and registry data while recommending local audits.

There is a clear clinical trend towards shorter courses, steroid‑sparing strategies and increased telehealth prescribing in rural cohorts.

Clinical Effectiveness In Australia

Do Australian prescribers see the same benefits reported overseas when they use Elocon?

Primary care practice in Australia mirrors international guidance: apply a thin layer once daily to affected areas for most adults, and use scalp lotions once daily for scalp dermatitis.

Local outcome data via PBS analyses are sparse for brand‑specific endpoints, and TGA adverse‑event reports offer signal detection rather than large‑scale trial outcomes.

Audit data from GP and community pharmacy records indicate Elocon and generics are commonly prescribed for atopic dermatitis flares and focal psoriasis and are associated with rapid itch reduction and better sleep within days for many patients.

In Indigenous and remote communities, barriers such as limited access, follow‑up and culturally appropriate education reduce effective use despite potency.

Telehealth e‑prescriptions have increased access to medicines but require pharmacist counselling to avoid prolonged unsupervised use and potential overuse.

Indications And Expanded Uses

What conditions is Elocon prescribed for, and when is specialist input needed?

• Approved Indications: Atopic dermatitis, eczema, psoriasis (generally avoid face/groin/axillae unless directed), lichen planus, seborrhoeic dermatitis.
• Scalp Use: Lotion/solution 0.1% once daily for scalp dermatitis.
• Prescription Status: Prescription only; review required for chronic disease management.

Off‑Label / Secondary Uses: Short‑term management of prurigo nodularis, certain lichenoid eruptions and other steroid‑responsive inflammatory dermatoses under specialist supervision.

1. Eczema: Chronic inflammatory skin disease with itch and flares.
2. Psoriasis: Localised plaque disease that may respond to potent topical steroids.
3. Lichen Planus: Inflammatory dermatosis often steroid responsive.

Adults normally apply a thin layer once daily, while paediatric use follows cautionary limits described in product guidance.

Composition And Brand Landscape

Which formulations are commonly stocked and what should pharmacists confirm at dispensing?

Mometasone furoate is the active ingredient (INN) and is a potent topical corticosteroid in ATC group D07AC13.

Available dosage forms include cream 0.1% (15g, 30g), ointment 0.1% (15g, 30g) and lotion 0.1% (30mL) with lotions preferred for scalp disease and creams/ointments for eczematous skin.

Pharmacists should confirm topical concentration and excipients before supplying, because some patients react to components such as propylene glycol or preservatives.

Packaging and leaflet language can vary internationally, so migrants may present with foreign‑labelled products; verify the active ingredient on any imported tube.

Contraindications And Special Precautions

Who should not use mometasone furoate, and what special monitoring is needed?

• Absolute Contraindications: Known hypersensitivity to mometasone furoate or any excipients; untreated bacterial, viral (including herpes simplex, varicella), fungal or parasitic skin infections; rosacea, acne vulgaris and perioral dermatitis.
• Relative Cautions: Children (risk of systemic absorption and skin atrophy), extensive broken skin, prolonged use or use under occlusion, elderly patients with fragile skin, pregnancy and lactation unless clearly needed and supervised.

In remote Indigenous settings where skin infections are common, ensure infection screening before starting a potent topical steroid and plan collaborative follow‑up.

Topical mometasone does not impair driving or workplace safety, but heavy wet‑work exposure may reduce skin barrier recovery and increase infection risk.

Dosage Guidelines (Australia)

What is the right way to use Elocon so it works and stays safe?

Adults: apply a thin layer once daily to affected areas; scalp lotions once daily for scalp dermatitis.

Treatment durations for acute flares are commonly 1–2 weeks; extend only under medical supervision.

Paediatrics: avoid use in children under 2 years; in children over 2 years use sparingly, prefer the shortest effective course (often less than 3 weeks) and avoid occlusion.

Elderly patients require monitoring for skin atrophy with prolonged treatment.

Missed dose: apply when remembered but do not double the next application.

Overuse risks include systemic corticosteroid effects such as Cushing’s syndrome and HPA‑axis suppression when used excessively, on large areas or on broken skin.

Storage: store at 25°C with permitted excursions to 15–30°C; protect from freezing and keep tube tightly closed.

When tapering is needed, step down to less potent agents or reduce frequency and introduce steroid‑sparing adjuncts such as emollients or topical calcineurin inhibitors under supervision.

Interactions Overview

Will Elocon mix badly with other drugs or foods?

Topical mometasone has minimal direct food or drink interactions and no alcohol or coffee conflicts.

Systemic interaction risk is low for standard topical use but additive HPA suppression can occur if the patient is receiving systemic corticosteroids concurrently.

Significant systemic absorption is uncommon, but if it occurs CYP3A4 inhibitors could theoretically affect metabolism of absorbed steroid; this is relevant only in extensive or prolonged topical overuse.

Avoid combining two potent topical steroids on the same site.

Concurrent use of topical calcineurin inhibitors can be a steroid‑sparing strategy when staged appropriately under clinician guidance.

Pharmacists should report suspected interaction‑related systemic effects to the TGA and advise escalation to GP or dermatologist when systemic signs appear.

Cultural Perceptions And Patient Habits In Australia

How do Australians actually buy and use Elocon, and what cultural issues matter?

Many patients shop by price and convenience at chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart, and telehealth has normalised online ordering.

Trust in pharmacists is high, with many patients seeking counselling at the pharmacy before starting a topical steroid.

Rural patients rely on telehealth and mail order, but limited local follow‑up may lead to prolonged unsupervised use.

Multicultural communities sometimes worry about visible effects such as hypopigmentation or atrophy and may bring overseas formulations with different labelling, so pharmacists should verify the active ingredient.

In Indigenous health settings, clinicians emphasise infection screening prior to steroid use and collaborative follow‑up plans.

Price sensitivity is common and PBS subsidy status influences brand choice and adherence.

Availability And Pricing Patterns (Australia)

Where can Australians get Elocon and how much should they expect to pay?

Elocon and generics are prescription only and commonly stocked by major chains and independent pharmacies across Australia.

Telehealth providers and accredited online pharmacies supply e‑prescriptions and mail delivery to metropolitan and remote patients.

Check the PBS and TGA ARTG for current subsidy and sponsor information because PBS listing varies by formulation and commercial sponsor.

Large discount retailers often undercut independents on price, although pharmacist counselling time and availability can differ.

Rural freight and logistics can add to retail cost for remote patients.

Caution: avoid unregulated online sellers that supply topical steroids without a prescription.

In our online pharmacy, elocon is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Comparable Medicines And Preferences

Which topical steroids are commonly used instead of mometasone and how do they compare?

Comparable agents in Australia include betamethasone (Betnovate, Diprosone) and fluticasone (Cutivate), which are group‑III potents like mometasone.

Clobetasol (Dermovate) is a superpotent option reserved for short specialist use on thick plaques where higher potency is required.

Choice depends on site (face and groin need lower potency), patient age, formulation preference and PBS coverage.

Pros and cons checklist: mometasone offers once‑daily dosing and good potency with tolerable side‑effect profile when used correctly; betamethasone is commonly used and often cheaper; clobetasol gives stronger plaque control but has higher atrophy risk.

FAQ Section

Is Elocon safe for children?

Use cautiously: not recommended under 2 years, and for children ≥2 years use the shortest effective course (preferably under 3 weeks) and avoid occlusion.

Can I use Elocon on my face?

Generally avoid facial use unless directed by a clinician because the face is more prone to atrophy and perioral dermatitis.

Can I buy Elocon over the counter in Australia?

No — it is prescription only in most jurisdictions; avoid unverified online sellers that do not require a prescription.

What if I miss a dose or use too much?

If you miss a dose apply when remembered and do not double the next dose; if you suspect prolonged overuse seek GP or pharmacist review as systemic steroid effects are possible with excessive application.

Red Flags For Urgent Review:

• Signs of secondary infection (increasing pain, spreading redness, pus).
• Widespread new rash or systemic symptoms such as weight gain or unusual fatigue suggesting systemic steroid effects.
• Rapid changes in skin colour or thinning at the application site.

Guidelines For Proper Use

What should pharmacists tell patients when dispensing Elocon?

1. Confirm diagnosis and exclude infection before supplying a potent topical steroid.
2. Demonstrate “thin layer” application using the fingertip unit concept and explain typical once‑daily use.
3. Recommend regular emollient use as first‑line and as a steroid‑sparing adjunct.
4. Set clear duration and arrange review within 1–2 weeks for acute flares.
5. Document treatment in eHealth/Script records and advise on safe disposal of unused tubes.

Definition: Fingertip Unit — the amount of cream from the tip of an adult index finger to the first crease, often used to guide dose by area.

Definition: Occlusion — covering the treated area with airtight dressing which increases steroid absorption and risk of side effects; avoid unless instructed by a clinician.

Telehealth Workflow Tips: send patient information electronically, confirm the pharmacy receives the e‑prescription, and arrange local follow‑up for rural patients who may lack easy face‑to‑face review.

Encourage reporting of adverse events to the TGA and counsel patients to avoid purchasing from unregulated online sources.

Delivery Across Australia